The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,584.00
Bid: 12,582.00
Ask: 12,586.00
Change: 68.00 (0.54%)
Spread: 4.00 (0.032%)
Open: 12,566.00
High: 12,632.00
Low: 12,512.00
Prev. Close: 12,516.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WRAPUP 9-Markets fall on Omicron fears as officials offer vaccine reassurance

Tue, 30th Nov 2021 03:07

(Adds markets, BioNTech)

* Drugmaker's CEO warns of 'material drop' in effectiveness

* Markets fall on fears of prolonged pandemic, but partly
recover

* Time needed to see if vaccines work against Omicron

* Variant first detected in Netherlands on Nov. 19

* Japan reports first case as new variant spreads

By Ludwig Burger and Emma Thomasson

FRANKFURT/BERLIN, Nov 30 (Reuters) - Financial markets fell
sharply on Tuesday after the head of drugmaker Moderna said
existing COVID-19 vaccines would be less effective against the
new Omicron variant, but they recovered strongly after more
reassuring comments from European officials.

European Medicines Agency (EMA) executive director Emer
Cooke told the European Parliament that existing vaccines will
continue to provide protection.

Andrea Ammon, chair of the European Centre for Disease
prevention and Control (ECDC), said the cases of Omicron so far
confirmed in 10 European Union countries were mild or without
symptoms, although in younger age groups.

The Pan-European STOXX 600 index, spooked by fears that
vaccine resistance https://www.reuters.com/world/how-worried-should-we-be-about-omicron-variant-2021-11-27
might trigger restrictions that would choke off a nascent
recovery, was down 0.5% at around 1644 GMT, having fallen as
much as 1.5% in early trade.

In New York at 1605 GMT, the Dow Jones Industrial Average
and the S&P 500 respectively were down about 1.3%
and 1.26%.

"There is no world, I think, where (the effectiveness) is
the same level?.?.?. we had with Delta," Moderna CEO Stephane
Bancel told the Financial Times https://www.ft.com/content/27def1b9-b9c8-47a5-8e06-72e432e0838f.

"I think it's going to be a material drop. I just don't know
how much because we need to wait for the data. But all the
scientists I've talked to?.?.?.are like 'this is not going to be
good'."

The University of Oxford said there was no evidence that
current vaccines would not prevent severe disease from Omicron https://www.reuters.com/business/healthcare-pharmaceuticals/how-fast-does-it-spread-scientists-ask-whether-omicron-can-outrun-delta-2021-11-29,
but that it was ready to rapidly update its shot, developed
with AstraZeneca, if necessary.

LAB TESTS

Moderna could not be reached for comment.

Regeneron Pharmaceuticals said its COVID-19 antibody
cocktail and other similar antiviral treatments could be less
effective against the latest variant.

News of Omicron's emergence had wiped roughly $2 trillion
off global stocks on Friday, after it was identified in southern
Africa and announced on Nov. 25.

Yet Dutch authorities said the variant had been detected in
the Netherlands as early as Nov. 19, before two flights arrived
from South Africa that were known to have carried the virus.

Cooke said lab tests for "cross neutralisation" would take
about two weeks. If there were a need to change COVID-19
vaccines, new ones could be approved within three or four
months, she added.

"Vaccination will likely still keep you out of the
hospital," said John Wherry, director of the Penn Institute for
Immunology in Philadelphia.

Moderna and fellow drugmakers BioNTech and Johnson & Johnson
are already working on vaccines that specifically target
Omicron. Moderna has also been testing a higher dose of its
existing booster.

BioNTech and Pfizer's vaccine will likely offer
strong protection against severe disease from the new variant,
BioNTech Chief Executive Ugur Sahin told Reuters.

Sahin said he expects lab tests to show some loss of
protection against mild and moderate disease due to Omicron but
the extent of that loss was hard to predict.

But border closures have already cast a shadow over economic
recovery just as parts of Europe see a fourth wave of infections
as winter sets in.

Bank of England policymaker Catherine Mann added to downbeat
comments from U.S. Fed Chairman Jerome Powell by
saying Omicron could hit consumer confidence, which would not
only weaken the British economy's recovery but could also could
push up inflation at the same time.

Many of the new travel restrictions have focused, to South
Africa's fury, on banning flights to and from southern Africa.

Japan confirmed its first case of the new variant on
Tuesday, in a traveller from Namibia. Australia found that a
person with Omicron had visited a busy shopping centre in Sydney
while probably infectious.

BORDER CONTROLS

Britain and the United States have both pushed their booster
programmes in response to the new variant. London said
international arrivals would have to self-isolate until they get
a negative result in a PCR test.

Greece said vaccination would be compulsory for the
over-60s, the group seen as most vulnerable to COVID-19.

Australia on Monday delayed the reopening of its
international borders by two weeks, less than 36 hours before
foreign students and skilled migrants were to be allowed back.

But in Germany, a current hotspot of the previous
significant variant, Delta, the seven-day average infection rate
fell slightly for the first time in three weeks after new
restrictions to slow transmission.

Sources said chancellor-in-waiting Olaf Scholz supported
making vaccination against COVID-19 compulsory and backed
barring the unvaccinated from non-essential stores.

Neighbouring Austria, which imposed its fourth full lockdown
last week after a surge in infections, also registered a drop.

But France registered its highest daily infection tally
since April.

And the Dutch health authority said Omicron was already
spreading in the Netherlands, where intensive care beds are
running out and measures including restrictions on hospitality
have yet to take effect.

The curbs on travellers from southern Africa have
highlighted the inequality of vaccine distribution, which may
have given the virus more opportunities to mutate.

WHO head Tedros Adhanom Ghebreyesus said he understood
concerns about Omicron, but added:

"I am equally concerned that several member states are
introducing blunt, blanket measures that are not evidence-based
or effective on their own, and which will only worsen
inequities."

The passenger liner Europa was docking in Cape Town on
Tuesday in what was meant to be the official start of the first
cruise ship season in South Africa's top tourist hub since the
pandemic.

After Omicron was discovered while they were at sea, many
passengers were expected to fly straight home.

(Reporting by Reuters bureaux worldwide; Writing by Himani
Sarkar and Kevin Liffey; Editing by Shri Navratnam, Andrew
Cawthorne, Nick Macfie and Angus MacSwan)

More News
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 09:41

LONDON BROKER RATINGS: Deutsche Bank starts Deliveroo at 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
12 Feb 2024 09:12

Barclays sees "compelling" entry point at AstraZeneca after recent falls

(Sharecast News) - Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.